Document:

Exhibit 10.1

 

NOCIMED, INC.

 

CONSULTING AGREEMENT

 

This Consulting
Agreement (this "Agreement") is made June 15, 2021 but effective as of March 1, 2021 (the "Effective Date"),
by and between Nocimed, Inc., a Delaware corporation (the "Company"), and Jeffrey Thramann ("Consultant")
(each a "Party" and together the "Parties").

 

1.            
Consulting Services. During the term of this Agreement.
Consultant will be appointed as Executive Director (an executive officer position) of the Company and will report
to the Company's Board of Directors. Consultant will also be appointed to the Company's Board of Directors. Consultant will provide
consulting services to the Company as described on Exhibit A hereto, as well as any other services mutually agreed to by
the Parties hereto from time to time (the "Services").

 

2.             
Fees. As consideration for the Services to be provided by Consultant, the Company shall pay to Consultant the cash and equity
compensation amounts specified in this Agreement (including Exhibit B hereto) at the times specified herein and therein.

 

3.             
Expenses. The Company will reimburse Consultant for necessary and reasonable business
expenses incurred in connection with performing the Services upon presentation of an itemized account and appropriate supporting documentation,
all in accordance with the Company's generally applicable policies.

 

		4.	Term and Termination.

 

(a)           
Consultant shall serve as a consultant to the Company for a period commencing on the Effective Date. Either party may terminate
this Agreement at any time upon l 0 days' written (or email) notice.

 

(b)          
As provided in Exhibit B hereto, the Consultant will be entitled to certain cash and equity compensation and in certain circumstances
relating to the termination of this Agreement As a precondition to receiving such termination compensation, Consultant must (i)
remain in compliance with all continuing obligations Consultant owes to the Company, including those set
forth under Consultant's Confidential Information Agreement (defined below), and (ii) promptly following
the termination, Consultant must sign and return to the Company, a separation agreement and release of claims in customary form (the "Release")
and allow the Release to become fully-effective and non-revocable by its terms. Consultant shall not be required to sign the Release in
order to receive payment of any accrued but unpaid cash fees earned hereunder prior to the termination date.

 

(c)           
For all purposes under this Agreement, "Cause" shall mean: (i) any willful failure substantially to perform Consultant's
duties and responsibilities to the Company; (ii) Consultant's commission of any act of fraud, embezzlement,
dishonesty or any other gross negligence or willful misconduct that has caused or is reasonably expected to result in material injury
to the Company; (iii) unauthorized use or disclosure by Consultant of any proprietary information
or trade secrets of the Company or any other party to whom Consultant owes an obligation of nondisclosure as a result of Consultant's
relationship with the Company; or (iv) Consultant's material breach of any of Consultants obligations under this Agreement the Confidential
Information Agreement (defined below), or any other written agreement or covenant with the Company; provided, that for clauses (i) and
(iv) above, the failure or breach will not be considered "Cause" unless to the extent the condition is curable, the Company
gives Consultant written notice of the condition within 30 days after the condition comes into existence and Consultant fails to remedy
the condition within 30 days after receiving written notice. No act or failure to act by Consultant shall be considered "willful"
unless committed without good faith and without a reasonable belief that the act or omission was in the Company's best interest.

 

5.             
Independent Contractor. Consultant’s relationship with the Company will be that of
an independent contractor and not that of an employee.

 

 

 

    	 	1	 

     

    

 

6.             
Method of Provision of Services. Consultant shall have sole direction, control and responsibility for determining the method,
details and means of performing the Services.

 

(d)           
No Benefits. Consultant acknowledges and agrees that Consultant shall not be eligible for any Company employee benefits
and, to the extent Consultant otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement,
Consultant hereby expressly declines to participate in such Company employee benefits.

 

(e)           
Taxes;. Indemnification. Consultant shall have full responsibility for applicable taxes for all compensation paid to Consultant
under this Agreement, including any withholding requirements that apply to any such taxes, and for compliance with all applicable labor
and employment requirements with respect to Consultant's self-employment, sole proprietorship or other form of business organization and
any U.S. immigration visa requirements. Consultant agrees to indemnify, defend and hold the Company harmless from any liability for, or
assessment of, any claims or penalties or interest with respect to such taxes, labor or employment requirements, including any liability
for, or assessment of, taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Consultant
or any liability related to the withholding of such taxes.

 

7.            
Confidential Information and Invention Assignment
Agreement. Consultant shall sign, or has signed, a Confidential Information and Invention Assignment
Agreement in substantially the form attached as Exhibit C hereto (the "Confidential Information Agreement"),
on or before the date Consultant begins providing the Services.

 

8.             
Consulting or Other Services for Competitors. Consultant represents and "warrants that
Consultant does not presently perform or intend to perform, and shall not perform, during the term of the Agreement, consulting or other
services for, or engage in or intend to engage in an employment relationship with, companies whose businesses or proposed businesses would
be directly competitive with the Company; provided, however, for the avoidance of doubt, Consultant may continue to work for Influence
Healthcare, and with Osler.

 

		9.	Miscellaneous.

 

(a)           
Governing Law. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions
pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the
laws of the Colorado, without giving effect to principles of conflicts of law.

 

(b)           
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the parties relating to the subject
matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements. whether oral or written, between
them relating to the subject matter hereof.

 

(c)           
Amendments and Waivers. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement,
shall be effective unless in writing signed by the parties to
this Agreement. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of that
provision as to that or any other instance.

 

(d)           
Assignment. No party to this Agreement may assign, whether voluntarily or by operation of law, this Agreement or any of
its rights and obligations under this Agreement, except with the prior written consent of the other party.

 

(e)           
Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall
be deemed sufficient when delivered personally or by overnight courier or sent by email, or 48 hours
after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at
such party's address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on
the signature page, at the most recent address set forth in the Company's books and records.

 

 

 

    	 	2	 

     

    

 

(f)           
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the
parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach
a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall
be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii)
the balance of the Agreement shall be enforceable in accordance with its terms.

 

(g)          
Construction. This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and
their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity
shall be construed in favor of or against any one of the parties hereto.

 

(h)           
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed an original, and all of which together shall constitute one and the same agreement. Execution of a facsimile copy will
have the same force and effect as execution of an original, and a facsimile signature will be deemed an original and valid signature.

 

(i)            
Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to this Agreement
or any notices required by applicable law or the Company's Certificate of Incorporation or Bylaws
by email or any other electronic means. Consultant hereby consents to (i)
conduct business electronically (ii) receive such documents
and notices by such electronic delivery and (iii) sign documents electronically and agrees to participate through an on-line or electronic
system established and maintained by the
Company or a third party designated by the Company.

 

(j)            Section
409A. For purposes of Internal Revenue Code Section 409A. the regulations and other guidance thereunder and any state law of
similar effect (collectively "Section 409A"), each payment that is paid pursuant to this Agreement is hereby
designated as a separate payment. For purposes of this Agreement, any reference to "termination" or "termination of
employment" or any similar term shall be construed to mean a "separation from service'' within the meaning of Section
409A. The parties intend that all payments made or to be made under this Agreement comply with, or are exempt from. the requirements
of Section 409A so that none of the payments or benefits will be subject to the adverse tax
penalties imposed under Section 409A, and any ambiguities herein will be interpreted to so comply or be so exempt. Notwithstanding
the foregoing, if any of the payments provided in connection with Consultant's separation from service do not qualify for any reason
to be exempt from Section 409A and Consultant is, at the time of Consultant's separation from service, a "specified
employee," as defined in Treasury Regulation Section 1.409A-l(i) (i.e., Consultant is a "key employee" of a publicly
traded company), each such payment will not be made until the first regularly scheduled payroll date of the 7th month
after Consultant's separation from service and, on such date (or, if earlier, the date of
Consultant's death), Consultant will receive all payments that would have been paid during such period in a single lump sum. In
addition, notwithstanding any other provision herein to the contrary, to the extent that any reimbursements or in-kind benefits
under this Agreement or otherwise constitute non-exempt "nonqualified deferred compensation" within the meaning of
Section 409A, then any such payments. reimbursements and/or benefits (i) shall be paid or reimbursed promptly but no later than
December 31st of the calendar year following the year in which the expense was incurred by Consultant, (ii) shall
not in any way affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other calendar year, and (iii) shall
not be subject to liquidation or exchange for another benefit.

 

[Signature Page Follows]

 

 

 

    	 	3	 

     

    

 

	 	

COMPANY:

	 	 
	 	NOCIMED, INC.
	 	 
	 	 
	 	By:	/s/ David K. Neal
	 	 	David K. Neal
	 	 	Chairman of the Board
	 	 	 
	 	Address:
	 	 
	 	XXXXXXXXX
	 	XXXXX, XX
	 	 
	 	Email: jpeacock@nocimed.com
	 	 	 
	 	 	 
	 	 	 
	 	CONSULTANT:
	 	 
	 	By:	/s/ Jeffrey Thramann, MD
	 	 	(Signature)
	 	 	 
	 	 	Jeffrey Thramann, MD
	 	 	PRINT NAME
	 	 	 
	 	 	 
	 	Address:
	 	XXXXXXXXX
	 	XXXXX, XX
	 	 
	 	Email: jeff@thramann.com

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	4	 

     

    

 

EXHIBIT A

 

DESCRIPTION OF CONSULTING
SERVICES

 

Consultant
is authorized to sign and deliver any agreement in the name
of the Company and to otherwise obligate the Company in any
respect relating to matters of the business of the Company, and to delegate such authority in his
or her discretion, provided only to the extent of such specific
matters delegated in writing to the Executive Director by the Company's Board of Directors
and which specific matters shall initially include the following:

 

Prior
to a consummation of the IPO, Consultant shall represent the Company in planning and conducting the IPO, and which shall include to interact
with partners, vendors, & employees, and to manage and direct the Company's preparation of information
and materials, and to provide personal services and conduct promotional activities, as such foregoing activities may be necessary and
required under such IPO-related engagement and process; provided, however, that any and all final terms of engagement with any underwriter
or similar outside party on Company's behalf in relation to the IPO, and/or final decisions related to formally filing for and entering
the IPO, and/or actually conducting and consummating the IPO,
must be approved by the Company's Board of Directors.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	5	 

     

    

 

EXHIBIT B

 

COMPENSATION

 

Cash Compensation:

 

	 	

	·	$25.000 per month, commencing as of March 1, 2021 (the "Monthly Fee").
	·	Accrued monthly (and pro-rated for any partial month) prior to the IPO.
	·	Accrued amounts payable within 10 days following the
consummation of the IPO (provided Consultant is still providing services at IPO effectiveness).

 

Equity Compensation:

 

	·	Stock
option grant under the Company's equity incentive plan.
	·	Grant
for 9,000,000 common shares total.
	·	The stock option grant will be subject to the terms and conditions set forth in the
Company's equity incentive plan.
	·	Stock
option grant shall provide for a net or cashless exercise.
	·	Grant will be made
promptly after the execution date of this Agreement.
	·	Exercise price per common share will be equal to the 409A fair market value as of the date of grant.
	·	The number of option grant shares and the per share exercise price of
the stock option grant shall be proportionately adjusted in the event of a stock split, reverse
stock split, stock dividend, combination, consolidation, reclassification of the shares of the Company's Common Stock or subdivision of
the shares of the Company's Common Stock.
	·	Ten year stock option term.
	·	Vesting:

		o	The stock option shall vest (in whole or in
part) upon consummation of the IPO based upon the Company Valuation reflected in the
terms of the IPO.
		o	Any portion of the stock option that does not vest pursuant
to the terms of the IPO shall be cancelled.
		o	The number of shares that vest upon an IPO shall equal:
(i) 0.1667, times (ii) the Company Valuation, divided by (iii)
the Share Price.
	 	o	Illustration #1: The Company completes the IPO where the Pre-Transaction Shares are 15 million, and the Share Price is $5. The
Company Valuation would be $75 million. 2,500,500 stock option grant shares would vest and 6,499,500 stock option grant shares would be
cancelled.
		o	Illustration #2: The Company completes the
IPO where the Pre-Transaction Shares are 20 million, and the Share Price is $5. The Company Valuation would be capped at the maximum 90
million. 3,000,600 stock option grant shares would vest and 5,999,400 stock option grant shares would be cancelled.
		o	Illustration #3: Prior to the IPO, the
                                                                                                    Company completes a 3-into-1 reverse stock split. The stock option grant is ratably adjusted into a grant for
                                                                                                    3 million shares (9 million divided by 3) with a per share
                                                                                                    exercise price of 0.78 ($0.26 grant date 409A price times three). The Company then completes the IPO where the Pre-Transaction Shares are 12 million, and the Share
Price is $5. The Company Valuation would be $60 million. 2,000,400 stock option grant shares would vest and 996,000 stock option grant
shares would be cancelled.

	·	"Companv
                                            Valuation" means the Company's "Pre-Transaction Shares" multiplied by
                                            the "Share Price.'' In no event shall the Company Valuation exceed $90 million.
	·	"Pre-Transaction Shares"
                                            means the number of the Company's outstanding common shares immediately prior to the effectiveness
                                            of the IPO (assuming conversion of all securities convertible into common stock and exercise
                                            of all outstanding options and warrants), but not including any shares of common stock reserved
                                            and available for future grant under any equity incentive or similar plan of the Company.
                                            Pre-Transaction Shares shall include only that portion of the Consultant's stock option that
                                            would become vested upon consummation of the IPO in accordance with the terms of the IPO.
	·	"Share
                                            Price" means the per common share initial public offering price (before underwriting
                                            discounts and commissions) set forth in the final prospectus for the IPO. In the event that
                                            the securities sold in the IPO include warrants in addition to common shares. the Share Price
                                            shall be calculated without regard to any offered warrants (as determined by the Company
                                            in good faith). By way of illustration, assume that the IPO provides for the offering of
                                            one unit (consisting of one common share and one common warrant) at a public offering price
                                            of $4.125 per unit. In such circumstance, the Company would determine that the Share Price
                                            would be $4.00 per common share and $0.125 would be attributed (consistent with underwriter
                                            typical practice) to the warrant.

 

 

 

    	 	6	 

     

    

 

Termination-Related
Compensation:

 

	·	Termination for Cause

		o	Consultant is paid accrued cash fees through termination date.
		o	Company may delay cash payout until closing of IPO, next round financing, sale of
Company, or SPAC acquisition.
		o	Any then unvested stock option terminates unvested.
		o	Any vested option has to be
exercised in the standard clean-up period under the equity incentive plan and then expires if not
exercised.

	·	Termination without  Cause

		o	Consultant is paid the greater of (i) accrued cash fees through termination date or (ii) $300k (if pre-IPO).

		o	Immediate payout.

		o	Option stays in effect for a 12 month post-termination "tail"
period.

		o	ff transaction (IPO, Sale/COC, SPAC acquisition) occurs during such tail period,
then the option will vest immediately prior to the closing of such transaction based upon the Company Value (as defined above) reflected
in such transaction.

		o	If after IPO, then vested option has to be exercised in the standard
clean-up period under the equity incentive plan and
then expires if not exercised.

	·	Voluntary Termination by Consultant

		o	Consultant is paid accrued cash fees through termination date.

		o	Company may delay cash payout until closing of IPO, next round financing, sale of Company,
or SPAC acquisition.

		o	Any then unvested stock
option terminates unvested.

		o	Any vested option has to be exercised in the
standard clean-up period under the equity incentive plan and then expires if
not exercised.

	·	Termination in connection with a Next Round Financing Closing Before March 1, 2022

		o	Consultant is paid the greater of (i) accrued cash fees through termination
date or (ii) $300k.

		o	Immediate payout.

		o	If Next Round Financing is with an Identified Party. then the option will not vest in
connection with the Next Round Financing transaction.
	 	o	If Next Round Financing is not with an Identified Party. then the option will vest immediately prior
to the closing of such Next Round Financing transaction based upon the Company Value.

		o	Identified
Party means: ___________(including any of their respective affiliates).

		o	Company Value shall be calculated in the method (and subject to the limitations
set forth above), except that the Pre-Transaction Shares and Share Price will be as reflected in
the terms of the next round financing.

		o	Option stays in effect for a 12 month post-termination "tail'· period.

	·	
 Termination in connection with a Sale or Change of Control of Company

		o	Consultant is paid the greater of (i) accrued cash fees through termination date or (ii) $300k.

		o	Immediate payout.

		o	If Sale/COC
                                            is with an Identified Party. then the option will not vest in connection with
                                            the Sale/COC transaction.

		o	If Sale/COC
                                            is not with an Identified Party, then the option will vest immediately prior
                                            to the closing of such transaction based upon
                                            the Company Value.
	 	o	
Company Value shall be calculated in the method (and subject to the limitations set forth
above). except that the Pre-Transaction Shares and Share Price will be as reflected in the terms of the Sale/COC transaction.

		o	If after IPO, then vested option has to be exercised
in the standard clean-up period under the equity incentive plan and then expires if not exercised.

		o	Sale/COC shall be defined to include a
private equity or similar financing transaction in which a new stockholder (including its affiliates)
acquires 50% or more of the Company’s combined voting power.

	·	Termination in connection with SPAC Acquisition

		o	Consultant is paid the greater of (i) accrued
                                            cash fees through termination date or (ii) $300k.

		o	Immediate payout.

		o	Option will vest immediately prior to the closing of such transaction based upon the
Company Value.
	 	o	Company
                                                                             Value shall be calculated in the method (and subject to the limitations set forth above). except that the Pre-Transaction Shares and
                                                                             Share Price will be as reflected in the terms of the SPAC acquisition.

 

 

 

    	 	7	 

     

    

 

EXHIBIT C

 

CONFIDENTIAL
INFORMATION AND INVENTION ASSIGNMENT AGREEMENT

 

[See Attached]

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	8Exhibit 10.2

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT
AGREEMENT (this “Agreement”) is entered into as of September 1, 2021 (the “Effective Date”)
by and between Nocimed Inc. a Delaware corporation (the “Company”) and Brent Ness (“Executive”).
This agreement supersedes and replaces the previous employment letter dated September 8, 2012 in its entirety.

 

RECITALS

 

A.            
The Company considers it essential to its best interests to procure the employment of Executive by the Company from and after the
date hereof.

 

B.             
Executive agrees to such employment on the terms hereinafter set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the parties agree
as follows:

 

1.             
Definitions. For purposes of this Agreement only (unless specified to the contrary), the following terms shall have the meanings
set forth below:

 

“Affiliate”
means, with respect to any individual or entity, (i) such individual’s spouse and lineal relations (whether natural or adopted)
and any trust formed and maintained solely for the benefit of such individual or such individual’s spouse or lineal relations and
(ii) any person or entity controlling, controlled by or under common control with such individual or entity, whether by ownership of voting
securities, by contract or otherwise.

 

“Cause” means any of the following:

 

(i)            
Executive’s willful and continued failure substantially to perform Executive’s duties in accordance with the Company’s
bylaws and written policies, and as directed by the Company Board; provided, however, that “Cause” shall not
be present under this clause unless (1) the Company shall have given Executive written notice specifying in reasonable detail the
event or circumstances constituting Cause under this clause, and (2) Executive fails to cure such event or circumstances within thirty
(30) days after such notice;

 

(ii)            Executive’s
material and willful breach of this Agreement, the Company’s Operating Agreement, the Proprietary Information Agreement or any
confidentiality or proprietary rights provisions contained herein or in separate agreements among Executive and the Company; provided,
however, that “Cause” shall not be present under this clause unless (1) the Company shall have given Executive
written notice specifying in reasonable detail the event or circumstances constituting Cause under this clause, and (2) Executive fails
to cure such event or circumstances within thirty (30) days after such notice;

 

(iii)          
Executive’s gross negligence or willful misconduct with respect to the Company, including but not limited to dishonesty in
the performance of Executive’s duties hereunder or conversion, misappropriation or embezzlement by Executive of any monies or property
of the Company; or

 

(iv)          
the institution of formal legal charges for, or conviction of Executive of fraud, embezzlement, any other offense involving dishonesty
or constituting a breach of trust, or any felony (or any crime in any jurisdiction other than the United States or any state thereof in
which the Company does business which would constitute such a felony under the laws of the United States or any state thereof).

 

 

 

    	 	1	 

     

    

 

“Code” means
the Internal Revenue Code of 1986, as amended.

 

“Company Board” means the board of directors of the Company.

 

“Disability”
means physical or mental incapacity resulting in Executive being unable to perform Executive’s duties for any consecutive 90-day
period, or for any 180 days during any consecutive 12-month period. Any question as to the existence of the Disability of Executive as
to which Executive and the Company cannot agree shall be determined in writing by a qualified independent physician as appointed by the
Company and Executive (or Executive’s representative). The determination of Disability made in writing to the Company and Executive
shall be final and conclusive for all purposes of this Agreement.

 

“Good Reason” means:

 

(i)            
Any material failure by the Company to comply with any of the provisions of this Agreement or any other agreement between Executive
and the Company pursuant to which Executive provides services, other than an isolated, insubstantial or other failure which can be remedied
and is remedied by the Company within 30 days after the Company’s receipt of written notice thereof from Executive;

 

(ii)           
Executive is assigned duties and responsibilities that represent a material diminution of the duties and responsibilities of the
Position, other than such assignments made with Executive’s written consent;

 

(iii)          
Executive’s Base Salary, as it may be increased from time to time, is decreased materially by the Company on a basis not
shared in common with all other senior executive officers of the Company as a group; or

 

(iv)          
Executive’s principal place of employment is moved more than forty (40) miles from Executive’s current principal place
of employment without Executive’s consent.

 

“Good Reason”
shall not be present unless (1) Executive shall have given the Company written notice specifying in reasonable detail the event or circumstances
constituting Good Reason within 30 days of the occurrence of such event or circumstances, (2) the Company fails to cure such event or
circumstances within thirty (30) days from the date of such notice from Executive and (3) Executive terminates Executive’s
employment within sixty (60) days of the end of the cure period. For purposes of clarification, if the Company cures an incidence of
Good Reason and a subsequent or separate incidence of Good Reason occurs, Executive must comply with all conditions set forth herein
for such separate or subsequent event.

 

2.             
Term of Employment. Subject to the provisions of Sections 5.1 through Section 5.3, inclusive, Executive shall be employed by
the Company for a period commencing on Executive’s first day of employment (the “Start Date”), which is expected
to be on September 1, 2021, and ending on the termination or resignation of Executive (the “Employment Term”). Executive’s
employment is “at will” and can be terminated by the Company or Executive at any time and for any reason, and nothing in this
Agreement shall be construed as an agreement or commitment of employment for any period of time. Upon termination of Executive’s
employment with the Company for any reason, the Company’s obligation to make payments hereunder shall cease, except that the Company
shall be required to make the payments set forth in Section 5 herein.

 

 

 

    	 	2	 

     

    

 

3.              Position.

 

(a)           
During the Employment Term, Executive shall be elected to and shall serve as Chief Executive Officer (the “Position”)
and in the performance of such duties shall report directly to the Company’s Board of Directors. Subject to applicable law and the
overall policy directives of the Company Board, Executive shall have all executive powers and authority which are necessary to enable
Executive to discharge Executive’s duties while serving in the Position and which are commonly incident to such Position consistent
with similar companies of a similar size. Executive shall perform all duties reasonably required by the Company, and if requested by the
Company, shall serve as an officer or director of the Company or any wholly- owned subsidiary.

 

(b)          
During the Employment Term, Executive shall in good faith perform the duties set forth in this Section 3 and shall devote substantially
all of Executive’s working time and efforts to the performance of such duties; provided, however, that Executive may devote time
to personal and family investments, industry related groups and board positions, not for profit boards and other activities to include
Executive’s existing engagement with K2 Capital Group to the extent that such activities do not materially conflict with the discharge
of Executive’s duties hereunder. The existence of any such material conflict shall be determined in good faith by the Company Board.

 

4.             Compensation.

 

4.1.          
Base Salary. The Company shall pay Executive an annual base salary (the “Base Salary”) at the initial
gross annual rate of $300,000, payable in regular installments in accordance with the Company’s usual payment practices but not
less frequently than semi-monthly during the Employment Term. The Company Board, or a compensation committee appointed by the Company
Board, shall annually review the Base Salary and determine changes in the Base Salary.

 

4.2.          
Bonus. With respect to each fiscal year, all or part of which is contained in the Employment Term (including the current
fiscal year), Executive shall be eligible to receive, in addition to Executive’s Base Salary, a cash or stock equivalent bonus
(the “Bonus”) of up to 50% of the Base Salary (“Target Amount”) for services rendered during such
fiscal year. For each fiscal year during the Employment Term, the Bonus will be based upon yearly or quarterly performance criteria (both
personal and for the Company), which will be determined by the Company Board and will be communicated to Executive in writing within
sixty (60) days following the start of the applicable fiscal year; provided, however, that for the current fiscal year, such performance
criteria will be set as a successful IPO onto Nasdaq or NYSE and satisfied with a bonus payment of $100,000 provided to Executive within
thirty (30) days of the IPO Closing Date. The Bonus in all other years will be paid no later than the date that is ninety (90) days following
the end of the fiscal year. Executive must continue to be employed by the Company on the payment date in order to be entitled to receive
the Bonus.

 

4.3           
Equity. The Board has approved an equity grant for Executive to receive and/or purchase shares of Common Stock that approximates
5% of the fully diluted shares after the pre-IPO reverse split and immediately prior to the IPO on the date of grant (the “Equity
Award”) pursuant to the Company’s Equity Incentive Plan (the “Plan”). The Equity Award will be in an
applicable award type as available in the Plan and shall vest monthly over four (4) years. In addition, the Equity Award will provide
that upon a Change of Control (as defined in the Plan), any shares subject to the Equity Award that are not vested as of the date of termination
will become fully vested on such date. The Company Board will continue to evaluate the equity position for the Executive in which additional
future grants may be awarded as deemed appropriate and subject to the Board approval.

 

 4.4            Benefits.

 

(a)           
Incentive Benefits. Executive will be entitled to participate in the Company’s compensation, incentive and benefit
plans and arrangements currently available or which may be made available to senior executives in the future, as amended from time to
time, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements on the
same terms as such benefits are provided to other senior executives of the Company. The Company, in its discretion, reserves the right
to amend or terminate such benefits at any time.

 

 

 

    	 	3	 

     

    

 

(b)           
Welfare Benefits. The Company shall also provide to Executive all vacation, health, major medical, hospitalization, life
insurance and disability insurance on the same terms as such benefits are provided to other senior executive officers of the Company.
The Company, in its discretion, reserves the right to amend or terminate such benefits at any time.

 

4.5            Business
Expenses and Perquisites. The Company shall promptly reimburse Executive for all out-of-pocket expenses paid by Executive in
connection with the performance of Executive’s duties hereunder pursuant to the Company’s policy for travel and expense
reimbursement. In addition, all reimbursements provided under this Agreement shall be made or provided in accordance with the
requirements of Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses
incurred during Executive’s lifetime (or during a shorter period of time specified in this Agreement); (ii) the amount of
expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year
following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits is not subject to
liquidation or exchange for another benefit.

 

4.6           
Place of Employment. The principal place of employment of Executive shall be within the Denver Metropolitan Area, or such
other location as is consented to by Executive in writing. It is understood, however, and agreed that Executive may be required, in connection
with the performance of Executive’s duties, to work from time to time at other locations designated by the Company Board or as required
in connection with the business of the Company. When required to travel to and/or spend time at such other locations, Executive’s
reasonable traveling and temporary living expenses shall be reimbursed by the Company, upon submittal of vouchers in accordance with Section
4.5.

 

5.            
Termination. Executive’s employment may be terminated by either party at any time. In the event of any such termination,
the rights of the parties will be determined as set forth in this Section 5. Executive acknowledges and agrees that any valid written
notice of termination by Executive delivered in accordance with the terms of this Agreement shall operate as a resignation by Executive
from the Position.

 

5.1.          
Termination For Cause by the Company. If Executive’s employment is terminated by the Company for Cause or due to Executive’s
death or Disability, (a) Executive shall be entitled to receive Executive’s Base Salary and unpaid accrued vacation through the
date of termination, (b) the Company shall reimburse Executive in accordance with Section 4.5 for expenses Executive has incurred in the
pursuit of Executive’s duties under this Agreement prior to the date of termination, and (c) Executive shall not be entitled to
receive any benefits from and after the date of termination, unless otherwise required by applicable law.

 

5.2.          
Termination of Employment Without Cause by the Company/Termination of Employment for Good Reason by Executive.

 

(a)           
If Executive’s employment is terminated by the Company without Cause, the Company shall provide Executive with thirty (30)
days’ written notice of termination setting forth the circumstances surrounding the termination (if any). In the event of such termination,
the Company shall, subject to subsection (c) below, pay Executive:

 

 (i)             Base Salary earned through the date of termination;

 

(ii)           
Base Salary for a period of twelve (12) months following the termination, to be paid on the Company’s regularly scheduled
payroll dates commencing within the first regular payroll date to occur following Executive’s delivery of an effective release of
claims as described in Section 5.2(c) below (the date such release is effective is the “Release Effective Date”); provided,
however, that any payments that would have otherwise been made prior to the Release Effective Date but for the fact that a release had
not yet been delivered, shall accrue and be paid in the first payroll date that follows such Release Effective Date, with subsequent payments
occurring on each subsequent Company payroll date (the “Severance Payments”);

 

 

 

    	 	4	 

     

    

 

(iii)          
if Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act
of 1985 or any similar state health insurance continuation program ("COBRA"), Company shall reimburse Executive for the monthly
COBRA premium paid by Executive. Such reimbursement shall be paid to Executive on the fifth (5) day of the month immediately following
the month in which Executive timely remits the premium payment. Executive shall be eligible to receive such reimbursement until the earliest
of: (i) the nine (9) month anniversary of the termination date; (ii) the date Executive is no longer eligible to receive COBRA continuation
coverage; and (iii) the date on which Executive becomes eligible to receive substantially similar coverage from another employer or other
source. Notwithstanding the foregoing, if Company's making payments under this Section would violate the nondiscrimination rules applicable
to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA
and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section in a manner as is necessary
to comply with the ACA;

 

(iv)         
reimbursement for expenses incurred but not yet reimbursed by the Company in the pursuit of Executive’s duties prior to the
date of termination in accordance with Section 4.5 of this Agreement to be paid within thirty (30) days of such termination;

 

(v)           
any Bonus earned for a completed fiscal year but not yet paid to be paid within the earlier of (A) thirty (30) days of such termination
and (B) the date that is ninety (90) days following the end of the fiscal year during which the Bonus is earned;

 

(vi)           any
other compensation and benefits to which Executive may be entitled under applicable plans, programs and agreements of the Company to
be paid, if applicable, within thirty (30) days of such termination or earlier if required by applicable law; and

 

(vii)         
unpaid vacation earned or accrued through Executive’s date of termination to be paid within thirty (30) days of such termination,
or earlier if required by applicable law.

 

(b)          
If Executive resigns for Good Reason, such resignation shall be treated for all purposes of this Agreement as a termination of
Executive’s employment without Cause.

 

(c)           
Any payment by the Company pursuant to this Section 5.2 is, to the extent permissible under applicable law, conditioned upon the
execution and effectiveness (including the execution of any non-revocation period) of a general release of claims, in a form reasonably
satisfactory to the Company in its discretion, which is to be provided to Executive no later than the date of Executive’s termination
of employment with the Company, of the Company, its Affiliates and any related parties signed by Executive. Such release shall be fully
effective no later than sixty (60) days following termination or Executive shall forfeit the Severance Payments under this Section 5.2.

 

5.3.          
Resignation Without Good Reason. If Executive resigns Executive’s employment with the Company for any reason (other
than Good Reason as provided in Section 5.2 hereof), Executive shall be entitled to the same payments Executive would have received if
Executive’s employment had been terminated by the Company for Cause.

 

5.4.          
No Mitigation or Offset. In the event of any termination of Executive’s employment under this Agreement, Executive
shall be under no obligation to seek other employment, and there shall be no offset against amounts due under this Agreement on account
of any remuneration attributable to any subsequent employment that Executive may obtain.

 

5.5.          
Nature of Payments. Any amounts due Executive under this Agreement in the event of any termination of Executive’s
employment with the Company are in the nature of severance payments, or liquidated damages which contemplate both direct damages and consequential
damages that may be suffered as a result of the termination of Executive’s employment, or both, and are not in the nature of a penalty.

 

5.6.          
Notice of Termination. Any purported termination of employment by the Company or resignation by Executive shall be communicated
by written notice to the other party hereto.

 

 

 

    	 	5	 

     

    

 

6.              Non-Competition: Non-Solicitation;
Non-Disparagement

 

6.1.          
Non-Competition. Executive acknowledges that during Executive’s employment Executive will have access to and knowledge
of the Company’s proprietary information and trade secrets and Executive’s Position is an executive level position in the
Company. To protect the Company’s proprietary information and trade secrets during Executive’s employment with the Company
whether full-time or part-time and for a period of twelve (12) months after the termination date of Executive’s employment with
the Company (the “Non- Competition Period”), Executive will not directly or indirectly engage in (whether as an employee,
consultant, proprietor, partner, director or otherwise), or have any ownership interest in, or participate in the financing, operation,
management or control of, any person, firm, corporation or business that engages in a “Restricted Business” in a “Restricted
Territory” (as defined below). It is agreed that ownership of (i) no more than one percent (1%) of the outstanding voting stock
of a publicly traded corporation, or (ii) any stock Executive presently owns will not constitute a violation of this provision. Executive
agrees and acknowledges that the time limitation on the restrictions in this Section 6, combined with the geographic scope, is reasonable.
Executive also acknowledges and agrees that this Section 6 is reasonably necessary for the protection of the Company’s proprietary
information and trade, that through employment Executive will receive adequate consideration for any loss of opportunity associated with
the provisions herein, and that these provisions provide a reasonable way of protecting the Company’s business value which will
be imparted to Executive. If any restriction set forth in this Section 6 is found by any court of competent jurisdiction to be unenforceable
because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it will be
interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.
As used herein, the terms: (a) “Restricted Business” means any material line of business conducted by the Company
during Executive’s employment with the Company and (b) “Restricted Territory” means any state, county, or locality
in the United States in which the Company conducts business as of the date of termination and any other country, city, state, jurisdiction,
or territory in which the Company does business as of the date of termination.

 

6.2.         
Non-Solicitation & Non-Interference. During the Non-Competition Period, Executive will not (a) directly or indirectly
induce any individual known to Executive to be an employee, independent contractor or consultant of the Company to terminate or negatively
alter his or her relationship with the Company or hire or assist any subsequent employer or Affiliated to hire any such person (b) solicit
the business of any individual or entity known to Executive to be a client or customer of the Company (other than on behalf of the Company)
in any manner that is competitive with the Company or (c) induce any individual or entity known to Executive to be a supplier, content
provider, vendor, consultant or independent contractor of the Company to terminate or negatively alter his, her or its relationship with
the Company. If any restriction set forth in this Section is found by any court of competent jurisdiction to be unenforceable because
it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it will be interpreted
to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

 

6.3.         
Non-Disparagement. Executive and the Company and its Affiliates agree not to disparage the other in any manner likely to
be harmful to them or their business or personal reputation. Notwithstanding the foregoing, nothing in this Agreement shall prohibit
any party from (a) making truthful statements or disclosures required by applicable law, regulation or legal process; (b) requesting
or receiving confidential legal advice; (c) engaging in communications protected under Section 7 of the National Labor Relations Act;
(d) responding to inquiries of a prospective employer; or (e) participating in any investigation by the federal Equal Employment Opportunity
Commission, the Department of Labor, or any other federal, state or local agency.

 

7.            
Proprietary Information. Executive will be required as a condition of employment to sign and abide by the Company’s Employee
Proprietary Information and Inventions Agreement (the “Proprietary Information Agreement”), a form of which is attached
hereto as Exhibit A. Nothing in the Proprietary Information Agreement shall limit or otherwise circumscribe any confidentiality
agreement Executive may have previously entered into with the Company. To the extent there are any conflicts between the terms of this
Agreement and those set forth in the Proprietary Information Agreement, the terms of this Agreement shall prevail and control.

 

 

    	 	6	 

     

    

 

8.             
Non-Compliance. Subject to the following sentence, but notwithstanding any other provision of this Agreement to the contrary
(specifically including the provisions of Section 5), if Executive breaches Section 6 or materially breaches the Proprietary Information
Agreement while employed by the Company, the Company may terminate the employment of Executive for Cause, and, whether or not Executive
is employed by the Company, from and after any such breach by Executive, the Company shall cease to have any obligations to make payments
to Executive under this Agreement. The Company shall give Executive written notice of an event or circumstances constituting a breach
of Section 6 or the Proprietary Information Agreement and, if Executive establishes the inadvertence of such breach to the reasonable
satisfaction of the Company, Executive shall have 30 days from the date of receipt of such notice to cure such event or circumstances,
if curable.

 

9.            
Specific Performance. Executive acknowledges and agrees that the Company’s remedies at law for a breach of any of the
provisions of Section 6 hereof would be inadequate and, in recognition of this fact, Executive agrees that, in the event of such a breach,
in addition to any remedies at law, the Company, without posting any bond, shall be entitled to obtain equitable relief in the form of
specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be
available.

 

10.          
Enforceability. It is expressly understood and agreed that although Executive and the Company consider the restrictions contained
in Section 6 hereof to be reasonable, if a final judicial determination is made by a court of competent jurisdiction that the time or
territory or any other restriction contained in this Agreement is an unenforceable restriction against Executive, the provisions of this
Agreement shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent
as such court may judicially determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that
the any restriction contained in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable,
such finding shall not affect the enforceability of any of the other restrictions contained herein.

 

11.          
Key Man Insurance. The Company may, at its sole cost and expense, secure a policy of Key Man life insurance on the life of
Executive, with death benefits payable to the Company. Executive shall have no right, title or interest in or to such insurance. Executive
shall cooperate with the Company in procuring such insurance by submitting to reasonable examinations and signing such applications or
other instruments as may be required by the insurance carriers with respect to such insurance.

 

12.          
Indemnification. In the event that Executive is made a party or threatened to be made a party to any action, suit, or proceeding,
whether civil, criminal, administrative, or investigative (a “Proceeding”), other than any Proceeding initiated by
Executive or the Company related to any contest or dispute between Executive and the Company or any of its affiliates with respect to
this Agreement or Executive’s employment hereunder, by reason of the fact that Executive is or was a director or officer of the
Company, or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, employee,
or agent of another corporation or a partnership, joint venture, trust, or other enterprise, Executive shall be indemnified and held harmless
by the Company to the maximum extent permitted under applicable law and the Company’s bylaws from and against any liabilities, costs,
claims, and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys’ fees). Costs
and expenses incurred by the Employee in defense of such Proceeding (including attorneys’ fees) shall be paid by the Company in
advance of the final disposition of such litigation upon receipt by the Company of: (i) a written request for payment; (ii) appropriate
documentation evidencing the incurrence, amount, and nature of the costs and expenses for which payment is being sought; and (iii) an
undertaking adequate under applicable law made by or on behalf of Executive to repay the amounts so paid if it shall ultimately be determined
that Executive is not entitled to be indemnified by the Company under this Agreement. Notwithstanding the foregoing to the contrary in
this Section, the Company shall not be required to indemnify Executive or hold Executive harmless for any gross negligence or intentional
misconduct by Executive.

 

 

 

    	 	7	 

     

    

 

13.           Miscellaneous.

 

13.1.        
Taxes. Executive agrees to be responsible for the payment of any taxes due on any and all compensation or benefit provided
by the Company pursuant to this Agreement. Executive agrees to indemnify the Company and hold the Company harmless from any and all claims
or penalties asserted against the Company for any failure to pay taxes due on any compensation or benefit provided by the Company pursuant
to this Agreement. Executive expressly acknowledges that the Company has not made, nor herein makes, any representation about the tax
consequences of any consideration provided by the Company to Executive pursuant to this Agreement. Executive expressly acknowledges that
the Company has not made, nor herein makes, any representation about the tax consequences of any consideration provided by the Company
to Executive pursuant to this Agreement. All forms of compensation referred to in this Agreement are subject to reduction to reflect
applicable required withholding and payroll taxes and other deductions required by law. Executive agrees that the Company does not have
a duty to design its compensation policies in a manner that minimizes Executive’s tax liabilities, and Executive will not make
any claim against the Company or the Company Board related to tax liabilities arising from Executive’s compensation. For purposes
of this Agreement, a termination of employment will be determined consistent with the rules relating to a “separation from service”
as defined in Section 409A of the Code and the regulations thereunder. Notwithstanding anything else provided herein, to the extent any
payments provided under this Agreement in connection with Executive’s termination of employment constitute deferred compensation
subject to Section 409A of the Code, and Executive is deemed at the time of such termination of employment to be a “specified employee”
under Section 409A of the Code, then such payment shall not be made or commence until the earlier of (i) the expiration of the 6-month
period measured from Executive’s separation from service from the Company or (ii) the date of Executive’s death following
such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse
tax treatment to Executive including, without limitation, the additional tax for which Executive would otherwise be liable under Section
409A of the Code in the absence of such a deferral. To the extent that any provision of this Agreement is ambiguous as to its compliance
with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder comply with Section 409A of
the Code. Payments pursuant to this Agreement are intended to constitute separate payments for purposes of Section 1.409A-2(b)(2) of
the Treasury Regulations. Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of
any in-kind benefit under this Agreement is determined to be subject to Section 409A of the Code, the amount of any such expenses eligible
for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses), in no event shall any
expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in
no event shall any right to reimbursement or the provision of any in-kind benefit be subject to liquidation or exchange for another benefit.

 

13.2.       
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Colorado without
giving any effect to any choice or conflict of law provision or rule (whether of the State of Colorado or any other jurisdiction) that
would cause the application of the laws of any jurisdiction other than the State of Colorado.

 

13.3.       
Waiver of Jury Trial. TO THE EXTENT PERMITTED BY LAW, THE PARTIES HERETO EACH WAIVE TRIAL BY JURY IN CONNECTION WITH ANY
DISPUTE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.

 

13.4.       
Entire Agreement: Amendments. This Agreement contains the entire understanding of the parties with respect to the employment
of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties
with respect to the subject matter herein other than those expressly set forth herein. This Agreement may not be altered, modified, or
amended except by written instrument signed by the parties hereto.

 

13.5.       
No Waiver. The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not
be considered a waiver of such party’s rights or deprive such party of the right thereafter to insist upon strict adherence to that
term or any other term of this Agreement.

 

 

 

    	 	8	 

     

    

 

13.6.       
Severability. In the event that any one or more of the provisions of this Agreement shall be or become invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be
affected thereby.

 

 13.7.         Assignment.

 

(a)           
Absent the prior written consent of the Company, this Agreement shall not be assignable by Executive, except that Executive may
assign payments due hereunder to a trust established for the benefit of Executive’s family or to Executive’s estate or to
any partnership or trust entered into by Executive and/or Executive’s immediate family members (meaning, Executive’s spouse,
lineal descendants, parents and siblings).

 

(b)           
Absent the prior written consent of Executive, this Agreement shall not be assignable by the Company, except that the Company may
assign this Agreement (i) in connection with a sale of substantially all of the assets of the Company or (ii) to an Affiliate.

 

13.8.       
Successors: Binding Agreement. This Agreement shall inure to the benefit of and be binding upon personal or legal representatives,
executors, administrators, successors, heirs, distributees, devisees and legatees of Executive and successors and assigns of the Company.

 

13.9.        
Notice. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be
in writing and shall be given to the respective addresses set forth on the execution page of this Agreement, provided that:

 

(a)           
all notices to the Company shall be directed to the attention of Nocimed, Inc., 951 Mariners Island Blvd, San Mateo, CA 94404,
Attn: Jeffrey Thramann, with a copy to James Carroll, Carroll Legal LLC, 233 McKinley Park Lane, Louisville, CO 80027.

 

(b)           
all notices to Executive shall be directed to Brent Ness, 14120 Fairway Lane, Broomfield, Colorado, 80023.

 

or to
such other address as either party may have furnished to the other in writing in accordance herewith. Each such notice or other communication
shall be effective (i) if given by prepaid overnight courier, upon receipt, (ii) if given by United States mail, postage prepaid, return
receipt requested, the later of actual receipt or three business days after deposit with the United States postal service, or (iii) upon
confirmed receipt of email; provided that notice of change of address shall be effective only upon receipt.

 

13.10.      
Withhold Taxes. The Company may withhold from any amounts payable under this Agreement such Federal, state and local taxes
as may be required to be withheld pursuant to any applicable law or regulation.

 

13.11.      
Counterparts. This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument.

 

[SIGNATURE PAGES FOLLOW]

 

 

 

    	 	9	 

     

    

 

IN WITNESS WHEREOF, the parties have
executed this Employment Agreement as of the date first above written.

 

	 	

COMPANY:

	 	 
	 	Nocimed, Inc.
	 	 
	 	 
	 	By:	/s/ David K Neal
	 	 	David K Neal
	 	 	Chairman of the Board
	 	 	 
	 	 	 
	 	 	 
	 	EXECUTIVE:
	 	 
	 	By:	/s/ Brent
Ness
	 	 	Brent
Ness
	 	 	Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	10	 

     

    

 

 

 

 

 

 

 

 

 

 

 

Exhibit A

 

Proprietary Information Agreement

 

[to be attached]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]